Turning Point Brands Announces First Quarter 2026 Results
-
Q1 2026 Modern
Oral Net Sales increased 133% to$52 .0 million, accounting for 42% of total company net sales, up from 21% in Q1 2025. -
Raising FY 2026 Modern
Oral Sales guidance; Introducing FY 2026 EBITDA guidance.
Q1 2026 Financial Highlights
(All results reflect comparisons to prior-year period)
-
Total Consolidated
Net Sales increased 16.8% to$124.3 million -
Stoker's segment
Net Sales increased 48.1% Zig-Zag segmentNet Sales decreased 22.4%
-
Stoker's segment
-
Gross Profit increased 14.6% to
$68.3 million -
Net Income decreased 19.0% to
$11.7 million -
Adjusted EBITDA decreased 6.5% to
$25.9 million (see Schedule A for a reconciliation to net income) -
Diluted EPS of
$0.60 and Adjusted Diluted EPS of$0.76 compared to$0.79 and$0.91 respectively, in the same period one year ago (see Schedule B for a reconciliation to Diluted EPS)
“We delivered a strong first quarter, driven by continued momentum in Modern Oral and disciplined execution across the portfolio,” said
Stoker’s Products Segment (70% of total net sales in the quarter)
For the first quarter, Stoker’s segment net sales increased 48.1% from the prior year to
For the first quarter, Stoker’s segment gross profit increased 39.1% from the prior year to
Zig-Zag Products Segment (30% of total net sales in the quarter)
For the first quarter,
For the first quarter,
Performance Measures in the First Quarter
Investment in the first quarter focused on sales and marketing efforts to support distribution and brand building. In the first quarter consolidated selling, general and administrative (“SG&A”) expenses increased 53.2% from the prior year to
As of
2026 Outlook
-
Full year Modern
Oral Gross Sales of$280-$300 million (from$220 -$240 million ) -
Full year Modern
Oral Net Sales of$210-$225 million (from$180 -$190 million ) -
Full Year Adjusted EBITDA of
$70-$90 million , inclusive of investment in Modern Oral sales, marketing, and trade promotions
Earnings Conference Call
As previously disclosed, a conference call with the investment community to review TPB’s financial results has been scheduled for
Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles in
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including our outlook for 2026 with respect to Modern
This press release contains TPB’s preliminary determinations and current expectations, and such information is inherently uncertain. The preliminary estimates provided herein have been prepared by, and are the responsibility of, management and are subject to completion of TPB's customary quarter-end closing and review procedures and third-party review. As a result, TPB's reported information in its Quarterly Report on Form 10-Q for the quarter ended
Financial Statements Follow on Subsequent Pages
|
|
||||||||
| Consolidated Statements of Income | ||||||||
| (dollars in thousands except share data) | ||||||||
| (unaudited) | ||||||||
|
|
|
Three Months Ended |
|
|||||
|
|
|
2026 |
|
|
2025 |
|
||
|
Net sales |
|
$ |
124,278 |
|
|
$ |
106,436 |
|
|
Cost of sales |
|
|
55,983 |
|
|
|
46,826 |
|
|
Gross profit |
|
|
68,295 |
|
|
|
59,610 |
|
|
Selling, general, and administrative expenses |
|
|
55,811 |
|
|
|
36,421 |
|
|
Operating income |
|
|
12,484 |
|
|
|
23,189 |
|
|
Other expense, net |
|
|
63 |
|
|
|
- |
|
|
Interest expense, net |
|
|
4,423 |
|
|
|
4,414 |
|
|
Investment gain |
|
|
(151 |
) |
|
|
(141 |
) |
|
Income from equity method investment |
|
|
(2,983 |
) |
|
|
(150 |
) |
|
Loss on extinguishment of debt |
|
|
- |
|
|
|
1,235 |
|
|
Income from continuing operations before income taxes |
|
|
11,132 |
|
|
|
17,831 |
|
|
Income tax (benefit) expense |
|
|
(2,810 |
) |
|
|
2,040 |
|
|
Consolidated net income |
|
|
13,942 |
|
|
|
15,791 |
|
|
Net income attributable to non-controlling interest |
|
|
2,275 |
|
|
|
1,396 |
|
|
Net income attributable to |
|
$ |
11,667 |
|
|
$ |
14,395 |
|
|
|
|
|
|
|
|
|
|
|
|
Basic income per common share: |
|
|
|
|
|
|
|
|
|
Net income attributable to |
|
$ |
0.61 |
|
|
$ |
0.81 |
|
|
Diluted income per common share: |
|
|
|
|
|
|
|
|
|
Net income attributable to |
|
$ |
0.60 |
|
|
$ |
0.79 |
|
|
Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
|
Basic |
|
|
19,214,389 |
|
|
|
17,795,243 |
|
|
Diluted |
|
|
19,474,877 |
|
|
|
18,249,306 |
|
|
|
|
Consolidated Balance Sheets |
|
(dollars in thousands except share data) |
|
(unaudited) |
|
|
|
|
|
|
|
|
||
|
ASSETS |
|
2026 |
|
|
2025 |
|
||
|
Current assets: |
|
|
|
|
|
|
|
|
|
Cash |
|
$ |
192,439 |
|
|
$ |
222,760 |
|
|
Accounts receivable, net of allowances of |
|
|
27,473 |
|
|
|
25,726 |
|
|
Inventories, net |
|
|
129,580 |
|
|
|
107,989 |
|
|
Other current assets |
|
|
68,712 |
|
|
|
60,675 |
|
|
Total current assets |
|
|
418,204 |
|
|
|
417,150 |
|
|
Property, plant, and equipment, net |
|
|
40,584 |
|
|
|
36,247 |
|
|
Right of use assets |
|
|
15,409 |
|
|
|
14,480 |
|
|
Deferred financing costs, net |
|
|
1,019 |
|
|
|
1,180 |
|
|
|
|
|
135,974 |
|
|
|
136,097 |
|
|
Other intangible assets, net |
|
|
63,731 |
|
|
|
64,042 |
|
|
Master Settlement Agreement (MSA) escrow deposits |
|
|
29,786 |
|
|
|
29,887 |
|
|
Other assets |
|
|
67,390 |
|
|
|
64,667 |
|
|
Total assets |
|
$ |
772,097 |
|
|
$ |
763,750 |
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
35,889 |
|
|
$ |
20,420 |
|
|
Accrued liabilities |
|
|
35,394 |
|
|
|
54,587 |
|
|
Total current liabilities |
|
|
71,283 |
|
|
|
75,007 |
|
|
Deferred income tax liability |
|
|
8,363 |
|
|
|
8,289 |
|
|
Notes payable and long-term debt |
|
|
293,885 |
|
|
|
293,625 |
|
|
Other long-term liabilities |
|
|
2,034 |
|
|
|
4,138 |
|
|
Lease liabilities |
|
|
11,043 |
|
|
|
10,708 |
|
|
Total liabilities |
|
|
386,608 |
|
|
|
391,767 |
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
|
|
|
|
Preferred stock, |
|
|
- |
|
|
|
- |
|
|
Common stock, voting, |
|
|
218 |
|
|
|
216 |
|
|
Common stock, nonvoting, |
|
|
- |
|
|
|
- |
|
|
Additional paid-in capital |
|
|
205,542 |
|
|
|
203,627 |
|
|
Cost of repurchased common stock (1,457,143 shares at |
|
|
(47,637 |
) |
|
|
(47,637 |
) |
|
Accumulated other comprehensive loss |
|
|
(2,090 |
) |
|
|
(1,563 |
) |
|
Accumulated earnings |
|
|
209,730 |
|
|
|
199,661 |
|
|
Non-controlling interest |
|
|
19,726 |
|
|
|
17,679 |
|
|
Total stockholders’ equity |
|
|
385,489 |
|
|
|
371,983 |
|
|
Total liabilities and stockholders’ equity |
|
$ |
772,097 |
|
|
$ |
763,750 |
|
|
|
||||||||
| Consolidated Statements of Cash Flows | ||||||||
| (dollars in thousands) | ||||||||
| (unaudited) | ||||||||
|
|
|
Three Months Ended |
|
|||||
|
|
|
2026 |
|
|
2025 |
|
||
|
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
|
Consolidated net income |
|
$ |
13,942 |
|
|
$ |
15,791 |
|
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
|
Loss on extinguishment of debt |
|
|
- |
|
|
|
1,235 |
|
|
Loss on sale of property, plant, and equipment |
|
|
- |
|
|
|
40 |
|
|
Income from equity method investment |
|
|
(2,983 |
) |
|
|
(150 |
) |
|
Gain on investments |
|
|
(15 |
) |
|
|
- |
|
|
Depreciation and other amortization expense |
|
|
1,753 |
|
|
|
1,309 |
|
|
Amortization of other intangible assets |
|
|
306 |
|
|
|
307 |
|
|
Amortization of deferred financing costs |
|
|
421 |
|
|
|
448 |
|
|
Deferred income tax expense |
|
|
96 |
|
|
|
1,716 |
|
|
Stock compensation expense |
|
|
2,938 |
|
|
|
1,664 |
|
|
Noncash lease income |
|
|
(807 |
) |
|
|
(380 |
) |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(1,941 |
) |
|
|
(5,539 |
) |
|
Inventories |
|
|
(21,700 |
) |
|
|
(8,310 |
) |
|
Other current assets |
|
|
(8,062 |
) |
|
|
(5,399 |
) |
|
Other assets |
|
|
(108 |
) |
|
|
(1,268 |
) |
|
Accounts payable |
|
|
15,637 |
|
|
|
15,433 |
|
|
Accrued liabilities and other |
|
|
(21,736 |
) |
|
|
512 |
|
|
Net cash (used in) provided by operating activities |
|
$ |
(22,259 |
) |
|
$ |
17,409 |
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
$ |
(5,139 |
) |
|
$ |
(2,185 |
) |
|
Payment for equity investments |
|
|
- |
|
|
|
(2,783 |
) |
|
Purchases of investments |
|
|
(2,283 |
) |
|
|
(714 |
) |
|
Proceeds from sale of investments |
|
|
2,351 |
|
|
|
500 |
|
|
MSA escrow deposits, net |
|
|
5 |
|
|
|
(48 |
) |
|
Net cash used in investing activities |
|
$ |
(5,066 |
) |
|
$ |
(5,230 |
) |
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|
Redemption of 2026 Notes |
|
$ |
- |
|
|
$ |
(250,000 |
) |
|
Proceeds from 2032 Notes |
|
|
- |
|
|
|
300,000 |
|
|
Payment of dividends |
|
|
(1,671 |
) |
|
|
(1,385 |
) |
|
Payments of financing costs |
|
|
- |
|
|
|
(6,582 |
) |
|
Exercise of options |
|
|
323 |
|
|
|
973 |
|
|
Redemption of options |
|
|
- |
|
|
|
(33 |
) |
|
Redemption of restricted stock units |
|
|
(330 |
) |
|
|
(1,828 |
) |
|
Redemption of performance based restricted stock units |
|
|
(1,014 |
) |
|
|
(2,625 |
) |
|
Net cash (used in) provided by financing activities |
|
$ |
(2,692 |
) |
|
$ |
38,520 |
|
|
|
|
|
|
|
|
|
|
|
|
Net (decrease) increase in cash |
|
$ |
(30,017 |
) |
|
$ |
50,699 |
|
|
Effect of foreign currency translation on cash |
|
$ |
(304 |
) |
|
$ |
(48 |
) |
|
|
|
|
|
|
|
|
|
|
|
Cash, beginning of period: |
|
|
|
|
|
|
|
|
|
Unrestricted |
|
$ |
222,760 |
|
|
$ |
48,941 |
|
|
Restricted |
|
|
1,914 |
|
|
|
1,961 |
|
|
Total cash at beginning of period |
|
$ |
224,674 |
|
|
$ |
50,902 |
|
|
|
|
|
|
|
|
|
|
|
|
Cash, end of period: |
|
|
|
|
|
|
|
|
|
Unrestricted |
|
$ |
192,439 |
|
|
$ |
99,640 |
|
|
Restricted |
|
|
1,914 |
|
|
|
1,913 |
|
|
Total cash at end of period |
|
$ |
194,353 |
|
|
$ |
101,553 |
|
Non-GAAP Financial Measures
To supplement our financial information presented in accordance with generally accepted accounting principles in
We define “EBITDA” as net income before interest expense, gain (loss) on extinguishment of debt, income tax expense, depreciation, amortization. We define “Adjusted EBITDA” as net income before interest expense, gain (loss) on extinguishment of debt, income tax expense, depreciation, amortization, other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Net Income” as net income excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Diluted EPS” as diluted earnings per share excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Operating Income (Loss)” as operating income (loss) excluding other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance.
Non-
In accordance with
| Schedule A | ||||||||
|
|
||||||||
|
|
||||||||
| Reconciliation of GAAP Net Income to Adjusted EBITDA | ||||||||
| (dollars in thousands) | ||||||||
| (unaudited) | ||||||||
|
|
||||||||
|
|
|
Three Months Ended |
|
|||||
|
|
|
|
|
|||||
|
|
|
2026 |
|
|
2025 |
|
||
|
Net income attributable to |
|
$ |
11,667 |
|
|
$ |
14,395 |
|
|
Add: |
|
|
|
|
|
|
|
|
|
Interest expense, net |
|
|
4,569 |
|
|
|
4,401 |
|
|
Loss on extinguishment of debt |
|
|
- |
|
|
|
1,235 |
|
|
Income tax (benefit) expense |
|
|
(2,492 |
) |
|
|
2,040 |
|
|
Depreciation expense |
|
|
794 |
|
|
|
828 |
|
|
Amortization expense |
|
|
1,285 |
|
|
|
822 |
|
|
EBITDA |
|
$ |
15,823 |
|
|
$ |
23,721 |
|
|
Components of Adjusted EBITDA |
|
|
|
|
|
|
|
|
|
Corporate restructuring (a) |
|
|
97 |
|
|
|
- |
|
|
ERP/CRM (b) |
|
|
- |
|
|
|
211 |
|
|
Stock based compensation (c) |
|
|
2,938 |
|
|
|
1,664 |
|
|
Transactional expenses and strategic initiatives (d) |
|
|
145 |
|
|
|
176 |
|
|
Non-recurring legal (e) |
|
|
153 |
|
|
|
- |
|
|
FDA PMTA (f) |
|
|
290 |
|
|
|
1,591 |
|
|
Mark-to-market gain on Canadian inter-company note (g) |
|
|
(116 |
) |
|
|
315 |
|
|
Tariff adjustment (h) |
|
|
5,903 |
|
|
|
- |
|
|
Manufacturing start-up costs (i) |
|
|
594 |
|
|
|
- |
|
|
Honorarium (j) |
|
|
63 |
|
|
|
- |
|
|
Adjusted EBITDA |
|
$ |
25,890 |
|
|
$ |
27,678 |
|
|
(a) |
Represents costs associated with corporate restructuring, including severance and early retirement. |
|
(b) |
Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses. |
|
(c) |
Represents non-cash stock options, restricted stock, PSRUs, etc. |
|
(d) |
Represents the fees incurred for transaction expenses. |
|
(e) |
Represents legal expenses incurred in connection with litigation related to an insurance claim. |
|
(f) |
Represents costs associated with applications related to FDA premarket tobacco production application ("PMTA").The PMTA regime requires the Company to submit an application to the FDA to receive marketing authorization to continue to sell certain of its product lines with continued sales permitted during the pendency of the applications. The application is a one-time resource-intensive process for each covered product line; however, due to the nature of the implementation process for those product lines already in the market, applications can take multiple years to complete rather than the typical one-time submission. The Company currently has only two product lines currently subject to the PMTA process, having utilized other regulatory pathway options available for our other product lines. The Company does not expect to submit additional PMTA applications for any new product lines after the submission for the pending two are complete. |
|
(g) |
Represents a mark-to-market loss attributable to foreign exchange fluctuation. |
|
(h) |
Represents adjustment to current period costs of goods sold to exclude tariffs subject to refund. |
|
(i) |
Represents non-recurring expenses incurred during the start-up of manufacturing lines. |
|
(j) |
Represents an honorarium gift included in other expense, net. |
| Schedule B | ||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||
| Reconciliation of GAAP Net Income to Adjusted Net Income and Diluted EPS to Adjusted Diluted EPS | ||||||||||||||||||||||||||||||||||||||||
| (dollars in thousands except share data) | ||||||||||||||||||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||
|
|
Three Months Ended |
|
|
Three Months Ended |
|
|||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
|
|
|
Income from continuing operations before income taxes |
|
|
Income tax expense (m) |
|
|
Net loss attributable to non- controlling interest |
|
|
Adjusted Net Income |
|
|
Adjusted Diluted EPS |
|
|
Income from continuing operations before income taxes |
|
|
Income tax expense (m) |
|
|
Net loss attributable to non- controlling interest |
|
|
Net Income |
|
|
Diluted EPS |
|
||||||||||
|
GAAP Net Income and Diluted EPS |
|
$ |
11,132 |
|
|
$ |
(2,810 |
) |
|
$ |
2,275 |
|
|
$ |
11,667 |
|
|
$ |
0.60 |
|
|
$ |
17,831 |
|
|
$ |
2,040 |
|
|
$ |
1,396 |
|
|
$ |
14,395 |
|
|
$ |
0.79 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss on extinguishment of debt (a) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,235 |
|
|
|
141 |
|
|
|
- |
|
|
|
1,094 |
|
|
|
0.06 |
|
|
Corporate restructuring (b) |
|
|
97 |
|
|
|
(24 |
) |
|
|
- |
|
|
|
121 |
|
|
|
0.01 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
ERP/CRM (c) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
211 |
|
|
|
24 |
|
|
|
- |
|
|
|
187 |
|
|
|
0.01 |
|
|
Stock based compensation (d) |
|
|
2,938 |
|
|
|
(742 |
) |
|
|
- |
|
|
|
3,680 |
|
|
|
0.19 |
|
|
|
1,664 |
|
|
|
190 |
|
|
|
- |
|
|
|
1,474 |
|
|
|
0.08 |
|
|
Transactional expenses and strategic initiatives(e) |
|
|
145 |
|
|
|
(37 |
) |
|
|
- |
|
|
|
182 |
|
|
|
0.01 |
|
|
|
176 |
|
|
|
20 |
|
|
|
- |
|
|
|
156 |
|
|
|
0.01 |
|
|
Non-recurring legal (f) |
|
|
153 |
|
|
|
(39 |
) |
|
|
- |
|
|
|
192 |
|
|
|
0.01 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
FDA PMTA (g) |
|
|
290 |
|
|
|
(73 |
) |
|
|
- |
|
|
|
363 |
|
|
|
0.02 |
|
|
|
1,591 |
|
|
|
182 |
|
|
|
- |
|
|
|
1,409 |
|
|
|
0.08 |
|
|
Mark-to-market loss on Canadian inter-company note (h) |
|
|
(116 |
) |
|
|
29 |
|
|
|
- |
|
|
|
(145 |
) |
|
|
(0.01 |
) |
|
|
315 |
|
|
|
36 |
|
|
|
- |
|
|
|
279 |
|
|
|
0.02 |
|
|
Tariff adjustment (i) |
|
|
5,903 |
|
|
|
(1,490 |
) |
|
|
- |
|
|
|
7,393 |
|
|
|
0.38 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
Manufacturing start-up costs (j) |
|
|
594 |
|
|
|
(150 |
) |
|
|
- |
|
|
|
744 |
|
|
|
0.04 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
Honorarium (k) |
|
|
63 |
|
|
|
(16 |
) |
|
|
- |
|
|
|
79 |
|
|
|
0.00 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
Tax benefit (l) |
|
|
- |
|
|
|
9,475 |
|
|
|
- |
|
|
|
(9,475 |
) |
|
|
(0.49 |
) |
|
|
- |
|
|
|
2,329 |
|
|
|
- |
|
|
|
(2,329 |
) |
|
|
(0.13 |
) |
|
Adjusted Net Income and Adjusted Diluted EPS |
|
$ |
21,199 |
|
|
$ |
4,124 |
|
|
$ |
2,275 |
|
|
$ |
14,800 |
|
|
$ |
0.76 |
|
|
$ |
23,023 |
|
|
$ |
4,963 |
|
|
$ |
1,396 |
|
|
$ |
16,664 |
|
|
$ |
0.91 |
|
|
(a) |
Represents loss on extinguishment of debt as a result of the redemptions of the 2026 Notes. |
|
(b) |
Represents costs associated with corporate restructuring, including severance and early retirement. |
|
(c) |
Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses. |
|
(d) |
Represents non-cash stock options, restricted stock, PSRUs, etc. |
|
(e) |
Represents the fees incurred for transaction expenses. |
|
(f) |
Represents legal expenses incurred in connection with litigation related to an insurance claim. |
|
(g) |
Represents costs associated with applications related to FDA premarket tobacco production application ("PMTA").The PMTA regime requires the Company to submit an application to the FDA to receive marketing authorization to continue to sell certain of its product lines with continued sales permitted during the pendency of the applications. The application is a one-time resource-intensive process for each covered product line; however, due to the nature of the implementation process for those product lines already in the market, applications can take multiple years to complete rather than the typical one-time submission. The Company currently has only two product lines currently subject to the PMTA process, having utilized other regulatory pathway options available for our other product lines. The Company does not expect to submit additional PMTA applications for any new product lines after the submission for the pending two are complete. |
|
(h) |
Represents a mark-to-market loss attributable to foreign exchange fluctuation. |
|
(i) |
Represents adjustment to current period costs of goods sold to exclude tariffs subject to refund. |
|
(j) |
Represents non-recurring expenses incurred during the start-up of manufacturing lines. |
|
(k) |
Represents an honorarium gift included in other expense, net. |
|
(l) |
Represents adjustment from quarterly tax rate to quarterly projected tax rate of 24% in 2026 and 21% in 2025. |
|
(m) |
Income tax expense calculated using the effective tax rate for the quarter of -25.2% in 2026 and 11.4% in 2025. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260507230137/en/
Investor Contacts
ir@tpbi.com
Source: